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Abstracts / Biol Blood Marrow Transplant 21 (2015) S30eS53 S31relapse, or transplant related mortality (TRM) (p¼0.2, p¼0.1,
p¼0.08, respectively). To investigate why higher CPSS scores
were associated with higher mortality, we performed analysis
restricted to patients with relapse following HCT. Those with
intermediate-2/high riskhadnearly two-fold increase in riskof
death after relapse compared to thosewith low/intermediate-
1 CPSS scores. Corresponding rates for low/intermediate-1 risk
groups,OSat1year, 3years, and5yearswere61%,48%, and44%
respectivelyand for intermediate-2/high riskgroupswere 38%,
32%, and19%respectively.OSofpatientswho receivedpre-HCT
treatment with hypomethylating agents, chemotherapy, or
both was not different compared to those who received no
therapy prior (p¼0.96).
In summary, CPSS scores, lower KPS scores, and bone
marrow as graft source were associated with poorer out-
comes following HCT.
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Introduction: A donor Killer Cell Ig-like Receptor (KIR) B-
Haplotye has been reported to beneﬁcially inﬂuence
outcome of unrelated transplantation for patients with acute
myeloid leukemia (AML) if the recipient HLA-C phenotype
exhibits a C1 ligand. We validated this association in an in-
dependent cohort of German patients.
Materials and Methods: Patients treated with ﬁrst unrelated
transplantation between 2000 and 2009 for a malignant
hematological disease were included (n¼1694, myeloid dis-
ease n¼982e58.0%, lymphatic diseases n¼712 e 42.0%). Graft
sources were bone marrow (n¼132 e 7.8%) or peripheral
blood stem cells (n¼1562e92.2%). All patients and donors
were high resolution typed for the loci HLA-A,B,C,DRB1,DQB1.
Retrospectively, the donors were typed for KIR genes using a
commercial SSP kit (Invitrogen) and classiﬁed for KIR-AA or
KIR-Bx haplotypes based upon the presence of one or more of
the following activating KIR-receptors: 2DL2, 2DL5, 3DS1,
2DS1, 2DS2, 2DS3, 2DS5. The resulting groups were compared
for the endpoints: relapse, transplant-relatedmortality (TRM),
and overall survival (OS) using competing risks analysis and
extended Cox regression modelling for the subsets myeloid
and lymphatic diseases. Heterogeneity of diagnosis within
each subset was adjusted using stratiﬁcation.
Results: For lymphatic diseases no signiﬁcant difference was
found between the corresponding groups regarding relapse,
OS and TRM. For myeloid diseases however, a signiﬁcantly
lower rate of relapse was found if the donor had a KIR Bx
haplotype and the patient had a C1 HLA-C ligand (5 year
relapse rate 36.2% vs 28.2%, p¼0.012). OS and TRM was
slightly favorable for this group, but no signiﬁcant differ-
ences could be found (OS: 42.2% vs. 37.9%, p¼0.146; TRM:
20.8% vs. 22.9% p¼0.433). The effect on relapse was inde-
pendent of the HLA-matching status, and a relative risk rate
of 0.73 (CI 0.57-0.92, p¼0.009) for the incidence of relapse
was found in multivariate competing risks regression after
correction for the number of HLA mismatches.
Conclusion: A substantially reduced relapse ratewas found in
our analysis for patients with myeloid diseases and the pres-
ence of an HLA-C1 ligand if their donor had a KIR-Bx Haplo-
type. Most patients being transplanted fall in this patient
group. Approximately two thirds of all donors have a KIR-Bx
haplotype. For patients with myeloid diseases and an HLA-C1
ligand, donor KIR typing should be performed if more than
one well matched donors are available. Donors with KIR-AA
haplotypes should be avoided for these patients if possible.10
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